Lisa Alderson

CEO of @adela_bio. Co-Founder of @GenomeMed and Clarified Precision Med. Board member | Advisor | Serial #entrepreneur. Global speaker on #Genomics.

[Adela @adela_bio]

We're excited to announce two presentations at #ASCO25 demonstrating the ability of Adela's tissue-agnostic test for MRD Detection and Response Monitoring to predict progression and identify non-responders to immunotherapy in solid tumors.

https://t.co/WrZxxLCk5T

[Adela @adela_bio]

Looking forward to engaging with the oncology community on how #liquidbiopsy and tissue-free approaches are advancing cancer detection and monitoring across the cancer continuum #ASCO26

If you’re attending, let’s connect.

#Oncology #Adela @ASCO @ConquerCancerFd @OncUpdates

[Lisa Alderson @LisaA]

Looking forward to joining Mara Aspinall of @illuminaventure on stage at #Tricon to discuss how to drive #innovation in precision medicine.

[Illumina Ventures @illuminaventure]

Heading to Precision Med #TRICON in San Diego? Catch Partner Mara Aspinall at two key sessions:

📅 3/11 | 3:40 PM PT – Driving Innovation in Precision Medicine
📅 3/12 | 8:00 AM PT – Investing in Precision Medicine

More info: https://t.co/4SHO3e57pU

@TriConference

[Illumina Ventures @illuminaventure]

Heading to Precision Med #TRICON in San Diego? Catch Partner Mara Aspinall at two key sessions:

📅 3/11 | 3:40 PM PT – Driving Innovation in Precision Medicine
📅 3/12 | 8:00 AM PT – Investing in Precision Medicine

More info: https://t.co/4SHO3e57pU

@TriConference

[Lisa Alderson @LisaA]

Jensen Huang, speaking at PMWC to a room full of healthcare pioneers, “Biology is one of the hardest problems. I’ve always hoped that your industry would have the benefit of our industry.”

“Artificial intelligence is finding intelligence in the data that you have.”

[Lisa Alderson @LisaA]

Adela demonstrates in a clinical validation study published in The Annals of Oncology the ability to detect recurrence up to 15 months in advance of clinical presentation (mean 4.1 months). Detecting early relapse can contribute to improved outcomes by guiding early intervention.

[Adela @adela_bio]

Today we are celebrating a significant milestone for Adela: the simultaneous publication of our clinical validation study for our tissue-agnostic MRD test in Head & Neck cancer in @Annals_Oncology and its presentation at #ESMO24. 

https://t.co/90Yscac7FQ

[Lisa Alderson @LisaA]

Exciting presentation at ESMO demonstrating Adela's ability to detect recurrence in Head & Neck Cancer patients up to 15 months in advance of imaging/clinical presentation with a mean lead time of 4.1 months. #precisiononcology

[Annals of Oncology @Annals_Oncology]

📢@ESMO24 concomitant paper: Clinical validation of a tissue-agnostic genome-wide methylome enrichment MRD assay for head and neck malignancies. #ESMO24 #HeadandNeckCancer @adela_bio @UHN_Research @decarvalho_lab @ScottBratman
https://t.co/3zXRaa6deV

[Adela @adela_bio]

Adela is presenting at #AACR2024! Highlights include data in head & neck cancer from our tissue-agnostic MRD assay, and Chief Scientific Officer @decarvalho_lab chairing the Plenary Session “Discovery Science in Early Cancer Biology and Interception”.
https://t.co/lt5Odw3nkI

[Lisa Alderson @LisaA]

@HeidiRehm congrats on your 2024 luminary award from #PMWC! It’s very well deserved.

[Adela @adela_bio]

Adela will be presenting data at #ESMO23 demonstrating strong prognostic prediction capabilities of our genome-wide methylome enrichment platform in Head and Neck Cancer and Renal Cell Carcinoma
https://t.co/MjNLsdhS6x

[Lisa Alderson @LisaA]

Thank you @SliceofHC - "Adela is poised to make significant strides in the realm of early cancer detection and MRD monitoring" https://t.co/dJzMfrVbcR
#precisionmedicine

[Lisa Alderson @LisaA]

https://t.co/V0ZezspT4W

[Lisa Alderson @LisaA]

Loved this! Thanks for hosting me @halletecco and thanks for the great questions @deenashakir and Michael Esquivel.

[Lisa Alderson @LisaA]

This is excellent @halletecco! I recommend this quick read to all entrepreneurs in healthcare.

[Lisa Alderson @LisaA]

@DivaBiotech Add outsourced tech dev to your list @DivaBiotech!

[Michael Esquivel @mtesquivel]

I'm excited to share ep. 1 of Closing Time is live! Tune in as @LisaA pitches her new startup to @Lux_Capital General Partner @deenashakir. Co-hosted with my longtime friend @halletecco, Closing Time gives a unique view into the exciting world of healthcare startups.

[Lisa Alderson @LisaA]

Here I sit down with #Illumina's Janina Jeff to share how genetics is being applied in clinical care today and how you may benefit from understanding your genetic insights. Watch here: https://t.co/fA33OIP949
#genomicmedicine #futureofhealthcare #digitalhealth #changemakers

[Lisa Alderson @LisaA]

It’s an exciting day for #genomics #startups! I am thrilled to be launching Illumina Ventures Labs alongside the Illumina Ventures team to provide #founders with access to #capital, fully equipped genomics labs in the US and UK and support from experienced operators.

[Illumina Ventures @illuminaventure]

Announcing the launch of Illumina Ventures Labs! Building on the Illumina Accelerator program, it will operate & provide access to fully equipped #genomics labs in the US & UK, mentorship & seed 💵 to attract a broad range of genomics related #startups.
https://t.co/OoDx6nAOWi

[Lisa Alderson @LisaA]

This is a great advancement in women's health. These new care plans combined with the Mirvie #RNA platform translates risk prediction into disease prevention and reduces complications from #preeclampsia.
#PrecisionHealth #PregnancyHealth

[Mirvie @MirvieDx]

BREAKING! The first-ever comprehensive care plan to prevent #preeclampsia has been published in @AJOG_thegray. This is a critical step in preventing preeclampsia and saving lives. Learn how it will help leapfrog #PregnancyHealth into the future: https://t.co/lr74tJexQ9

[Lisa Alderson @LisaA]

https://t.co/R8iBmC4vu6